A similar study, assessing 103 pediatric ALL triplets (87 BCP and 16 T-cell ALL), observed that relapse-specific somatic alterations were enriched in 12 genes (NR3C1, NR3C2, TP53, NT5C2, FPGS, CREBBP, MSH2, MSH6, PMS2, WHSC1, PRPS1, and PRPS2), all of which were involved in the drug response. The gene discussed is MSH2; the disease is acute lymphoblastic leukemia.